Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

14.22
-0.0150-0.11%
Post-market: 14.280.0625+0.44%19:59 EDT
Volume:11.92M
Turnover:169.86M
Market Cap:6.44B
PE:-20.14
High:14.75
Open:14.45
Low:13.95
Close:14.23
52wk High:15.30
52wk Low:1.76
Shares:452.97M
Float Shares:394.00M
Volume Ratio:0.40
T/O Rate:3.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7058
EPS(LYR):-1.0941
ROE:-40.36%
ROA:-20.31%
PB:8.75
PE(LYR):-12.99

Loading ...

Iovance Biotherapeutics to Present at Upcoming Conference

GlobeNewswire
·
May 21

What Iovance Biotherapeutics (IOVA)'s Amtagvi Momentum and Narrowing Losses Means For Shareholders

Simply Wall St.
·
May 15

Iovance Biotherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
May 08

Iovance Biotherapeutics price target lowered to $14 from $16 at Chardan

TIPRANKS
·
May 08

BUZZ-U.S. STOCKS ON THE MOVE-Krispy Kreme, Tesla, Axon Enterprise

Reuters
·
May 08

Sector Update: Health Care

MT Newswires Live
·
May 08

BUZZ-Iovance Biotherapeutics falls on Q1 revenue miss

Reuters
·
May 07

Iovance Biotherapeutics Shares Fall 12% Premarket After Wider-Than-Expected Q1 Adj. Loss

THOMSON REUTERS
·
May 07

Stock Track | Iovance Biotherapeutics Plunges 7.09% in Pre-market After Missing Q1 Earnings and Revenue Estimates

Stock Track
·
May 07

Iovance Biotherapeutics Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $71.430M Miss $78.396M Estimate

Benzinga Earnings
·
May 07

BRIEF-Iovance Biotherapeutics Q1 Revenue USD 71.43 Million

Reuters
·
May 07

Iovance Biotherapeutics Inc - Guides Q2 2026 Revenue $86 Mln-$88 Mln, FY2026 $350 Mln-$370 Mln

THOMSON REUTERS
·
May 07

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

GlobeNewswire
·
May 07

Earning Preview: Iovance Biotherapeutics, Inc. this quarter’s revenue is expected to decrease by 4.05%, and institutional views are bullish

Earnings Agent
·
May 01

Iovance Biotherapeutics to report first-quarter results, host conference call and webcast

Reuters
·
Apr 27

Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026

GlobeNewswire
·
Apr 27

Will FDA’s RP1 Setback Refocus Iovance Biotherapeutics' (IOVA) Post-Checkpoint Melanoma Narrative?

Simply Wall St.
·
Apr 22

Iovance grants 135,470 inducement stock options priced at $3.8 per share

Reuters
·
Apr 18

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 18

Iovance Biotherapeutics announces annual shareholder meeting webcast

Reuters
·
Apr 18